Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report

doi:10.21037/apm-20-1244

	Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report
	Zhou, Qinfei 2,3; Zhao, Jiazheng 3,4; Wang, Jie 1; Bao, Guanai 3,5; Gong, Li-Yan 2,3
刊名	ANNALS OF PALLIATIVE MEDICINE
	2020-07-01
卷号	9
关键词	Small-cell lung cancer (SCLC) immunotherapy durvalumab third-line treatment case report
ISSN号	2224-5820
DOI	10.21037/apm-20-1244
通讯作者	Gong, Li-Yan(susang409@hotmail.com)
英文摘要	The global incidence and mortality rates of lung cancer are the highest of any cancer. Small-cell lung cancer (SCLC) is an undifferentiated carcinoma which accounts for 15-20% of all lung cancers. Compared with the other major lung cancer type, non-small cell lung cancer, SCLC exhibits worse biological behavior, has a higher degree of malignancy, and develops more rapidly. The majority of SCLC present with extensive-stage disease, and the prognosis for these patients remains poor. Recently, immunotherapy has been demonstrated clinical activity in extensive-stage SCLC (ES-SCLC); however, the efficacy and safety of immunotherapy in ES-SCLC needs further confirmation. Durvalumab, a selective, high-affinity human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80, showed durable clinical activity and a manageable safety profile in patients with pretreated ES-SCLC as a first-line treatment. Here, we report the case of an ES-SCLC patient who achieved complete remission (CR) of local lesions after receiving durvalumab monotherapy as a third-line treatment, experiencing no obvious immune-related side effects, such as rash, diarrhea, fatigue, myelosuppression, or thyroid dysfunction. No immune-related pulmonary or hepatorenal toxicities occurred. The case suggests that immunotherapy can be selected for third-line or multi-line treatment of ES-SCLC, and anti-PD-L1 antibody may be the better choice for patients who have poor performance status (PS) scores.
资助项目	Zhejiang Provincial Traditional Chinese Medicine Fund[2019ZB018] ; Zhejiang Provincial Medical and Health Scientific and Technical Fund[2020374375] ; Zhejiang Provincial Natural and Science Fund[LY19H290001]
WOS关键词	CISPLATIN
WOS研究方向	Health Care Sciences & Services
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000555045100119
资助机构	Zhejiang Provincial Traditional Chinese Medicine Fund ; Zhejiang Provincial Medical and Health Scientific and Technical Fund ; Zhejiang Provincial Natural and Science Fund
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/102919]
专题	中国科学院合肥物质科学研究院
通讯作者	Gong, Li-Yan
作者单位	1.Jinhua Guangfu Canc Hosp, Dept Oncol, Jinhua, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Rare & Head & Neck Oncol, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Canc & Basic Med IBMC, 1 East Banshan Rd, Hangzhou, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Head & Neck Surg, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Integrated Chinese Tradit Med & Western Med, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Zhou, Qinfei,Zhao, Jiazheng,Wang, Jie,et al. Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report[J]. ANNALS OF PALLIATIVE MEDICINE,2020,9.
APA	Zhou, Qinfei,Zhao, Jiazheng,Wang, Jie,Bao, Guanai,&Gong, Li-Yan.(2020).Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report.ANNALS OF PALLIATIVE MEDICINE,9.
MLA	Zhou, Qinfei,et al."Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report".ANNALS OF PALLIATIVE MEDICINE 9(2020).